26
|
Fernandes AR, Mortimer D, Holmes M, Rose M, Zhihua L, Huang X, Smith F, Panton S, Marshall L. Occurrence and spatial distribution of chemical contaminants in edible fish species collected from UK and proximate marine waters. ENVIRONMENT INTERNATIONAL 2018; 114:219-230. [PMID: 29522986 DOI: 10.1016/j.envint.2018.02.047] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/12/2017] [Revised: 02/13/2018] [Accepted: 02/26/2018] [Indexed: 05/27/2023]
Abstract
The occurrence of a range of regulated and emerging organic environmental contaminants was investigated in 182 samples of edible marine fish sampled mainly from UK marine regions, but extending northerly to the coast of Norway and south to the Algarve. These species (sprats, mackerel, turbot, halibut, herring, grey mullet, sea bass, grey mullet, sardines, etc.) are among those considered to be at the highest risk of contamination with regulated contaminants such as polychlorinated dibenzo-p-dioxins and dibenzofurans (PCDD/Fs, dioxins), and polychlorinated biphenyls (PCBs), but the occurrence of polybrominated diphenylethers (PBDEs) and polybrominated biphenyls (PBBs) was also investigated. Sub-sets of samples (50-75) were also analysed for emerging contaminants: polychlorinated naphthalenes (PCNs), polybrominated and mixed halogenated dibenzo-p-dioxins, dibenzofurans and biphenyls (PBDD/Fs, PXDD/Fs and PXBs) and perfluoroalkyl substances (PFAS). Contaminant occurrence varied with species and location, but all measured contaminants were detected, with sprats, sea bass, sardines, mackerel, and herring showing higher tissue concentrations. The concentrations of the different contaminants in the various samples were mapped utilising the GPS coordinate data of the capture locations to visualise spatial distribution levels. In terms of catch location, fish sampled from the coasts of southern Britain, north-western France and the Irish Sea appeared to contain proportionately higher levels of some contaminants - e.g. samples from the Irish Sea tended to show higher PCN concentrations, whereas higher levels of PCBs were observed in some fish sampled off the coasts of northern France. Similarly, samples of mullet from the southeast coast of UK showed much higher concentrations of BDE-99 than the other regions. In terms of occurrence trends, PCDD/F and PCB concentrations show a modest decline over the last decade but where limited background data is available for emerging contaminants, there is no evidence of downward trends.
Collapse
|
27
|
Boon A, See Hoe L, Pederson S, Obonyo N, Wells M, Bartnikowski N, Passmore M, Marshall L, James L, Tung J, Suen J, Macdonald P, McGiffin D, Fraser J. Inflammatory Cytokine Profiles in 24-Hour Brain Stem Death Model. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
28
|
Shiarli A, Smyth G, Carcellar F, Vaidya S, Marshall L, Zacharoulis S, Powell K, Conti L, Frost D, Saran F, Mandeville HC H. PO-0843: Outcomes of paediatric diffuse intrinsic pontine gliomas treated with hypofractionated radiotherapy. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31153-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
29
|
Hernandez-Suarez DF, Núñez-Medina H, Scott SA, Lopez-Candales A, Wiley JM, Garcia MJ, Melin K, Nieves-Borrero K, Rodriguez-Ruiz C, Marshall L, Duconge J. Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy. Drug Metab Pers Ther 2018; 33:49-55. [PMID: 29408797 PMCID: PMC5840033 DOI: 10.1515/dmpt-2017-0032] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2017] [Accepted: 12/18/2017] [Indexed: 01/06/2023]
Abstract
BACKGROUND Antiplatelet therapy with clopidogrel is recommended to reduce cardiovascular events in patients with peripheral artery disease (PAD); however, clopidogrel efficacy has not been adequately studied in this patient population. Therefore, we aimed to determine the effects of cilostazol therapy on platelet reactivity among PAD patients on clopidogrel. METHODS We performed a cross-sectional pilot study of 46 Puerto Rican patients diagnosed with PAD. The cohort was divided based on use of clopidogrel and cilostazol (n=24) or clopidogrel alone (n=22). Platelet function was measured ex vivo using the VerifyNow P2Y12 assay. Genomic DNA was extracted from peripheral blood samples using the QIAamp DNA Blood Midi Kit, which was subjected to candidate variant genotyping (CYP2C19, ABCB1, PON1 and P2RY12) using TaqMan quantitative polymerase chain reaction assays. All analyses were performed using SAS version 9.4 (SAS Institute). RESULTS Among all enrolled patients, 18 (39%) had high on-treatment platelet reactivity (HTPR). The mean platelet reactivity was 207±53 (range, 78-325) with higher P2Y12 reaction units in the non-cilostazol group, 224±45 vs. 191±55 on the cilostazol group (p=0.03). No significant differences were observed in the clinical or genetic variables between the two groups. A multiple regression analysis determined that history of diabetes mellitus (p=0.03), use of cilostazol (p=0.03) and hematocrit (p=0.02) were independent predictors of platelet reactivity. CONCLUSIONS In Puerto Rican PAD patients on clopidogrel therapy, history of diabetes mellitus, use of cilostazol and hematocrit are independent predictors of platelet reactivity. Adjunctive cilostazol therapy may enhance clopidogrel efficacy among PAD patients with HTPR.
Collapse
|
30
|
Fernandes GS, Sarmanova A, Warner S, Harvey H, Akin-Akinyosoye K, Richardson H, Frowd N, Marshall L, Stocks J, Hall M, Valdes AM, Walsh D, Zhang W, Doherty M. Knee pain and related health in the community study (KPIC): a cohort study protocol. BMC Musculoskelet Disord 2017; 18:404. [PMID: 28934932 PMCID: PMC5609004 DOI: 10.1186/s12891-017-1761-4] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/04/2017] [Accepted: 09/13/2017] [Indexed: 04/10/2023] Open
|
31
|
Nysom K, Leblond P, Frappaz D, Aerts I, Varlet P, Giangaspero F, Gambart M, Hargrave D, Marshall L, Kearns P, Makin G, Gallego S, Kieran M, Casanova M, Lahogue A, Wind S, Stolze B, Roy D, Uttenreuther-Fischer M, Geoerger B. Biomarker prevalence study and phase I trial of afatinib in children with malignant tumours. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx363.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
32
|
Koo P, Schneider K, Moelle M, Marshall L. P112 Investigations of general cognitive ability on the efficiency of slow oscillatory-tDCS. Clin Neurophysiol 2017. [DOI: 10.1016/j.clinph.2016.10.235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
33
|
Stone J, Waern S, Khabra K, Wharram B, Middleton A, Edwards L, Kuhlthau K, Crouch C, Marshall L, Zacharoulis S, Vaidya S, Powell K, Saran F, Yock T, Mandeville H. Impact of toxicities and neurocognitive impairment on the health related quality of life (HR-QoL) for survivors of medulloblastoma. Eur J Cancer 2017. [DOI: 10.1016/s0959-8049(17)30631-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
34
|
Wimmer K, Rody A, Merseburger A, Guo X, Wünsch L, Birnbaum W, Marshall L, Hiort O. Intraabdominelles Seminom bei einer Patientin mit kompletter Androgenresistenz. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
35
|
Akkoc N, Zerbini C, Karateev D, Pedersen R, Vlahos B, Marshall L, Bao C, Al-Maini M, Shen Q. THU0065 Potential Predictors for Achieving and/or Maintaining Low Disease Activity or Remission in Patients with Rheumatoid Arthritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
36
|
Tanaka Y, Smolen J, Jones H, Szumski A, Marshall L, Emery P. THU0031 Baseline Characteristics and Treatment Outcomes of Patients Who Achieve Deep Remission in Rheumatoid Arthritis: Table 1. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1784] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
37
|
Lau C, Gibofsky A, Damjanov N, Lula S, Marshall L, Jones H, Emery P. THU0126 Dose Titration of Biologics for The Treatment of Rheumatoid Arthritis and Ankylosing Spondylitis: A Systematic Literature Review: Table 1. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1840] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
38
|
Maksymowych W, Wichuk S, Dougados M, Jones H, Szumski A, Marshall L, Bukowski J, Lambert R. SAT0378 Modification of Structural Lesions on Magnetic Resonance Imaging by Etanercept: A 12-Week Randomized Placebo-Controlled Trial. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
39
|
Marshall L, Wilson N, Gleeson K. Psychological recovery from facial injury following interpersonal assault: a narrative analysis. Br J Oral Maxillofac Surg 2015. [DOI: 10.1016/j.bjoms.2015.08.173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
40
|
Aw D, Thain J, Ali A, Aung T, Chua WM, Sahota O, Weerasuriya N, Marshall L, Kearney FC, Masud T. 45FRACTURE RISK PREDICTION AND TREATMENT THRESHOLDS USING FRAX, GARVAN AND QFRACTURE IN AN OSTEOPOROSIS CLINIC POPULATION. Age Ageing 2015. [DOI: 10.1093/ageing/afv108.02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
Nayak A, Hao Z, Sadek R, Dobbins R, Marshall L, Vahanian N, Ramsey J, Kennedy E, Mautino M, Link C, Lin R, Royer-Joo S, Morrissey K, Mahrus S, McCall B, Pirzkall A, Munn D, Janik J, Khleif S. 346 Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30209-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
42
|
Aw D, Thain J, Ali A, Aung T, Chua W, Sahota O, Weerasuriya N, Marshall L, Kearney F, Masud T. P-003: Comparison of FRAX and QFracture use in an osteoporosis clinic population in determining whether to treat or not to treat in fallers versus non-fallers. Eur Geriatr Med 2015. [DOI: 10.1016/s1878-7649(15)30106-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
43
|
Reddy S, Scher J, Szumski A, Hsu MA, Marshall L, Jones H, Yazici Y. SAT0584 Comparative Performance of Rapid3 (Routine Assessment of Patient Index Data 3) Versus Other Composite Indices in Clinical Trials of Psoriatic Arthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2381] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
44
|
Mackay A, Vinci M, Burford A, Bjerke L, Taylor K, Nandhabalan M, Marshall L, Molinari V, Popov S, Ingram W, Moore A, Trabelsi S, Hmida D, Mu K, Bidinotto L, Reis R, Ng HK, von Bueren A, Baudis M, Jones C. HG-11 * INTEGRATIVE MOLECULAR META-ANALYSIS OF 700 PEDIATRIC HIGH GRADE GLIOMA AND DIPG DEFINES WIDESPREAD INTER- AND INTRA-TUMORAL HETEROGENEITY. Neuro Oncol 2015. [DOI: 10.1093/neuonc/nov061.48] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Sieper J, Jones H, Bukowski J, Pedersen R, Mahgoub E, Marshall L. THU0209 Responder vs Non-Responder Baseline Characteristics and Early Response in Patients with Non-Radiographic Axial Spondyloarthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
46
|
Sugiyama N, Murata T, Morishima Y, Fukuma Y, Shibasaki Y, Marshall L. THU0359 Treatment Pattern and Direct Cost of Biologics for Rheumatoid Arthritis (RA) Patients: A Real-World Analysis of Nationwide Japanese Claims Data. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
47
|
Emery P, Jones H, Marshall L, Szumski A, Kerkmann U, Kola B. FRI0130 Continuation of Etanercept Monotherapy After Achievement of Remission with Etanercept and Methotrexate Combination Therapy: Subanalysis from the Comet Study. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
48
|
Kemeny L, Amaya M, Cetkovska P, Rajatanavin N, Lee WR, Szumski A, Marshall L, Mahgoub EY, Aldinç E. Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial. BMC DERMATOLOGY 2015; 15:9. [PMID: 25994179 PMCID: PMC4494170 DOI: 10.1186/s12895-015-0028-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/10/2014] [Accepted: 05/04/2015] [Indexed: 11/10/2022]
Abstract
BACKGROUND Psoriasis prevalence and characteristics in Asia, Central Europe, and Latin America have not been thoroughly investigated and there are no large trials for biologic treatments for patients from these regions. The goal of this analysis was to report clinical response to anti-tumor necrosis factor-alpha treatment in these patients. METHODS Patients from Argentina, Czech Republic, Hungary, Mexico, Taiwan, and Thailand (N=171) were included in this subset analysis of the PRISTINE trial. Patients with stable moderate-to-severe plaque psoriasis were blinded and randomized to receive etanercept 50 mg once weekly (QW) or biweekly (BIW) for 12 weeks, followed by 12 weeks of open-label QW treatment with etanercept 50 mg through week 24 (QW/QW vs. BIW/QW). Concomitant methotrexate (≤20 mg/week) and mild topical corticosteroids or other agents were permitted at the physician's discretion, in accordance with therapeutic practice. RESULTS As early as week 8, 26.7 % in the etanercept QW group and 44.0 % in the BIW group achieved Psoriasis Area and Severity Index (PASI) 75. At weeks 12 and 24, respectively, PASI 75 increased to 39.5 % and 62.8 % in the QW/QW group and 66.7 % and 83.3 % in the BIW/QW group. PASI 75 was significantly different between treatment groups from week 8 through the end of study (p<0.05). The Kaplan-Meier estimate of the proportions achieving PASI 75 in QW/QW and BIW/QW groups, respectively, was 27.4 % and 45.8 % through week 8; 41.9 % and 68.7 % through week 12; and 72.5 % and 95.2 % through week 24. CONCLUSIONS Treatment with etanercept 50 mg provided rapid relief of psoriasis symptoms in patients from Asia, Central Europe, and Latin America. A more rapid response was observed in patients who received BIW treatment for the first 12 weeks which was sustained after reducing to QW dosing for the subsequent 12 weeks. Response rates were similar to those observed in the overall PRISTINE population. TRIAL REGISTRATION ClinicalTrials.gov identifier NCT00663052 .
Collapse
|
49
|
Birnbaum W, Marshall L, Hiort O. Transition in the field of Disorders of Sex Development (DSD): A case of late diagnosed 5α-reductase deficiency illustrates complex requirements. Exp Clin Endocrinol Diabetes 2015. [DOI: 10.1055/s-0035-1549085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
50
|
Ong T, Tan W, Sahota O, Marshall L. 85 * ARE FRACTURES AND A DIAGNOSIS OF OSTEOPOROSIS IN THE ELDERLY RELATED TO SOCIAL DEPRIVATION. Age Ageing 2014. [DOI: 10.1093/ageing/afu038.10] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|